GSK PLC (GSK) — research page
UK · uk-cm-kg/LSE/GSK · as of 2026-11-06
Identity and listing
The issuer is GSK PLC, listed on the LSE Main Market under ticker GSK, ISIN GB00BN7SWP63, LEI 5493000HZTVUYLO1D793. Its security type is Corporate, segment SET1, sector Pharmaceuticals and Biotechnology [201030], jurisdiction England and Wales (Companies House jurisdiction field). Status on the record is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | GSK PLC | source · 2026-11-06 |
| exchange | LSE Main Market | source · 2026-11-06 |
| ticker | GSK | source · 2026-11-06 |
| ISIN | GB00BN7SWP63 | source · 2026-11-06 |
| LEI | 5493000HZTVUYLO1D793 | source · 2026-11-09 |
| security type | Corporate | source · 2026-11-06 |
| segment | SET1 | source · 2026-11-06 |
| sector | Pharmaceuticals and Biotechnology [201030] | source · 2026-11-06 |
| jurisdiction | England and Wales (Companies House jurisdiction field) | source · 2026-11-06 |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 346 filings in the twelve months to 2026-11-06, across 177 filing days. The median gap between filing days is 1.0 days. Days from the latest filing to the record date is 0. The exchange median cadence gap is 4 days and the sector median cadence gap is 6.0 days. The exchange median filings count is 29.0 and the sector median is 42. The exchange median latency is 3 days and the sector median latency is 4.0 days. The latest filing is dated 2026-11-06 and is of type corporate_action.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 346 | 1 | 0 |
| exchange median: LSE Main Market (892 issuers) | 29 | 4 | 3 |
| sector median: Pharmaceuticals and Biotechnology [201030] (51 issuers) | 42 | 6 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-06 | corporate_action | GSK publishes provisional dividend dates | |
| 2026-11-06 | ch_capital | capital allotment shares — 2026-10-30 | |
| 2026-11-03 | newswire_release | Alamar Biosciences Partners with GSK on Large-Scale | |
| 2026-11-02 | corporate_action | Total Voting Rights | |
| 2026-10-30 | ch_capital | capital allotment shares — 2026-10-23 |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is Deloitte LLP. Its location is not on the record. Auditor changes are not on the record.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. Status on the halt flag is listed, not halted.
Orderability
For the elective professional client category the outcome is signal ACM-200, determinable. For the eligible counterparty category the outcome is signal ACM-200, determinable. The rule version is acm-68000/uk/product-governance-fca-prod-sourcebook/r1, with chapter as of 2026-11-04.
| client category | outcome |
|---|---|
| elective professional client | ACM-200 |
| eligible counterparty | ACM-200 |
rule acm-68000/uk/product-governance-fca-prod-sourcebook/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's own investor-relations page names 14 research houses: Barclays, Berenberg, BNP Paribas Exane, Citi, Deutsche Bank, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, TD Cowen, UBS and Wolfe Research.
| research house | analyst | source · read date |
|---|---|---|
| Barclays | issuer page · 2026-11-12 | |
| Berenberg | issuer page · 2026-11-12 | |
| BNP Paribas Exane | issuer page · 2026-11-12 | |
| Citi | issuer page · 2026-11-12 | |
| Deutsche Bank | issuer page · 2026-11-12 | |
| Goldman Sachs | issuer page · 2026-11-12 | |
| Guggenheim Securities | issuer page · 2026-11-12 | |
| Jefferies | issuer page · 2026-11-12 | |
| JP Morgan | issuer page · 2026-11-12 | |
| Morgan Stanley | issuer page · 2026-11-12 | |
| Redburn | issuer page · 2026-11-12 | |
| TD Cowen | issuer page · 2026-11-12 | |
| UBS | issuer page · 2026-11-12 | |
| Wolfe Research | issuer page · 2026-11-12 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The issuer has no sealed years on the record. The market's vintage is not sealed. The live record began on 2026-09-11. Years 2021 to 2026 are sealed in the store but not served as of a date, and the as-of door answers not_sealed.
Sources
11 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (identity.exchange)
- 10.2
- https://api.londonstockexchange.com/api/gw/lse/instruments/alldata/GSK (identity.isin)
- 10.3
- https://find-and-update.company-information.service.gov.uk/company/03888792 (identity.jurisdiction)
- 10.4
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.5
- https://www.londonstockexchange.com/stock/GSK/gsk-plc/company-page (identity.sector)
- 10.6
- https://mcp.uk-cm-kg.ai/events/LSE/GSK (the disclosure lines)
- 10.7
- https://marketsecurities.fca.org.uk/officiallist (the halt flag)
- 10.8
- https://india-pharma.gsk.com/media/scfg3eux/annual-report-2025-26.pdf (the auditor)
- 10.9
- https://mcp.uk-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.10
- https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus (coverage)
- 10.11
- https://mcp.uk-cm-kg.ai/record/LSE/GSK (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"GB00BN7SWP63"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:50c0183e361fd3ad.